Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Dr Soliman Abdul Kader Fakeeh Hospital Co Debt-to-EBITDA?
Dr Soliman Abdul Kader Fakeeh Hospital CoSAU:4017 +0.26%15 Debt-to-EBITDA is 2.67 as of Jun. 2026, which is 16% above its 10-year median of 2.30. GuruFocus rates SAU:4017 with a GF Score™ of 15/100. The stock has 3 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Dr Soliman Abdul Kader Fakeeh Hospital Co ranks worse than 58.79% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SAU:4017's Debt-to-EBITDA is ranked worse than 58.79% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs SAU:4017: 2.84
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Dr Soliman Abdul Kader Fakeeh Hospital Co Debt-to-EBITDA Related Terms
Dr Soliman Abdul Kader Fakeeh Hospital Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Soliman Abdul Kader Fakeeh Hospital Co Debt-to-EBITDA Chart
Dr Soliman Abdul Kader Fakeeh Hospital Co Annual Data
Trend
Dec23
Dec24
Dec25
Debt-to-EBITDA
4.30
1.98
2.30
Dr Soliman Abdul Kader Fakeeh Hospital Co Quarterly Data
SAU:4017 vs HCA, THC, EHC: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Dr Soliman Abdul Kader Fakeeh Hospital Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Soliman Abdul Kader Fakeeh Hospital Co Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dr Soliman Abdul Kader Fakeeh Hospital Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dr Soliman Abdul Kader Fakeeh Hospital Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Dr Soliman Abdul Kader Fakeeh Hospital Co (SAU:4017) has a Debt-to-EBITDA of 2.67 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dr Soliman Abdul Kader Fakeeh Hospital Co. This is 16% above median its historical median of 2.30. Over the past decade, Dr Soliman Abdul Kader Fakeeh Hospital Co's Debt-to-EBITDA has ranged from 1.98 to 4.30. According to the industry distribution chart, Dr Soliman Abdul Kader Fakeeh Hospital Co ranks #281 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 58.8%.
Is Dr Soliman Abdul Kader Fakeeh Hospital Co's Debt-to-EBITDA too high?
Dr Soliman Abdul Kader Fakeeh Hospital Co's current Debt-to-EBITDA of 2.67 is 16% above median its 10-year median of 2.30. Over the past 10 years, this metric has ranged from a low of 1.98 to a high of 4.30. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Dr Soliman Abdul Kader Fakeeh Hospital Co's value of 2.67 is 22.2% above this industry median. Based on the distribution chart, Dr Soliman Abdul Kader Fakeeh Hospital Co ranks #281 out of 478 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Dr Soliman Abdul Kader Fakeeh Hospital Co has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Dr Soliman Abdul Kader Fakeeh Hospital Co's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dr Soliman Abdul Kader Fakeeh Hospital Co ranks #281 out of 478 companies for Debt-to-EBITDA. This places Dr Soliman Abdul Kader Fakeeh Hospital Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. Dr Soliman Abdul Kader Fakeeh Hospital Co's value of 2.67 is 22.2% above this benchmark. Historically, Dr Soliman Abdul Kader Fakeeh Hospital Co's own Debt-to-EBITDA has ranged from 1.98 to 4.30 over the past decade. While the company's 10-year median is 2.30 vs. the industry median of 2.19, Dr Soliman Abdul Kader Fakeeh Hospital Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr Soliman Abdul Kader Fakeeh Hospital Co's current Debt-to-EBITDA of 2.67 is 22.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dr Soliman Abdul Kader Fakeeh Hospital Co. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr Soliman Abdul Kader Fakeeh Hospital Co's current Debt-to-EBITDA is 2.67, which is 16% above median its own 10-year median of 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Soliman Abdul Kader Fakeeh Hospital Co stock overvalued right now?
Dr Soliman Abdul Kader Fakeeh Hospital Co (SAU:4017) has a current Debt-to-EBITDA of 2.67. The current Debt-to-EBITDA is 2.67, which is 16% above median its 10-year median of 2.30 and 22.2% above the Healthcare Providers & Services industry median of 2.19. Dr Soliman Abdul Kader Fakeeh Hospital Co's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Dr Soliman Abdul Kader Fakeeh Hospital Co (SAU:4017), the current Debt-to-EBITDA is 2.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dr Soliman Abdul Kader Fakeeh Hospital Co is a company whose principal activities include managing, establishing, and operating hospitals, clinics, medical, educational, and training centers. In addition to the above, the company is also managing and operating medical services, analysis and radiology laboratory, and managing and establishing pharmacies, wholesale and retail of medical equipment, maintenance of IT equipment, and software-related services. The group has three reportable segments, including medical services, which generates maximum revenue, education, trading, retail, and others. Geographically, it principally operates in the Kingdom of Saudi Arabia.
15GF Score
Get the complete analysis for SAU:4017
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4017 has been successfully added to your 
